Compare Bristol-Myers Squibb Co (BMY) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Alphabet Inc Class A — how do they compare? Bristol-Myers Squibb Co trades at $57.41 (market cap $116.30B), while Alphabet Inc Class A trades at $362.35 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 37.6× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | GOOGL | |
|---|---|---|
Market Cap | $116.30B | $4.37T |
Sector | Health | Media |
52-Week High | $62.37 | $402.62 |
52-Week Low | $42.60 | $182.00 |
Enterprise Value | $152.24B | $4.34T |
Dividend Yield | 4.42% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Alphabet (GOOGL) trades at $352.51, down 1.31% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 27.42, net income margin of 37.92%, and consistent earnings beats in recent quarters. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube subscription price increases, while cash flow trends improved to a net positive $7.24B in 2025.
The outlook remains positive with an 85% analyst buy rating and a $431.78 consensus price target, supported by robust revenue growth and AI expansion. Key risks include antitrust scrutiny and market volatility, but the company's financial health and strategic positioning suggest long-term upside for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
